Fig. 7: Targeting of TNF-α during chemotherapy restores anti-tumor immunity and prolongs survival. | Nature Communications

Fig. 7: Targeting of TNF-α during chemotherapy restores anti-tumor immunity and prolongs survival.

From: Spatial tumor immune heterogeneity facilitates subtype co-existence and therapy response in pancreatic cancer

Fig. 7

a KPC cells were orthotopically implanted into syngeneic C57BL6/J mice and treated with an anti-TNF-α antibody in combination with gemcitabine (GEM) chemotherapy, or vehicle control (VC). b Kaplan-Meier survival analysis of a. Median survival indicated. Log-rank test. VC, n = 5 animals. c H&E staining of anti-TNF-α + GEM and VC tumors. Scale bar 100 μm. d IF for CD45 with CD68, and CD45 with TNF-α, in anti-TNF-α + GEM and VC tumors. Scale bar 50 μm. Quantification of (d) for CD45/CD68 (e) and TNF-α/CD45 (f) double-positive cells. Per-animal average counts per FOV with mean ± s.d. shown. VC, n = 4 animals; anti-TNF-α + GEM, n = 5 animals. g, IHC for CD3 and CD8 in orthotopically transplanted anti-TNF-α + GEM and VC tumors. Scale bar: overview, 100 μm; insert, 30 μm. Quantification of (g) for CD3+ (h) and CD8+ (i) cells. Per-animal average percentage of positive cells with mean ± s.d. shown. n = 5 animals. e, f, h, i Two-tailed Student’s t-test with Welch’s correction. j Model of AP1 dichotomy in PDAC subtype co-existence and immune recruitment. Source data are provided as a Source Data file.

Back to article page